8-K: Rafael Holdings Reports Sharply Reduced Quarterly Loss, Bolstered by Cyclo Therapeutics Merger and $25 Million Capital Raise Ahead of Key Phase 3 Trial Results

Rafael Holdings, Inc. announced a significant reduction in net losses for its third fiscal quarter and first nine months of 2025, driven by the absence of prior year's large non-cash expenses, while confirming the completion of its merger with Cyclo Therapeutics and a $25 million rights offering, with pivotal Phase 3 clinical trial results for Trappsol Cyclo expected later this month.

Summary

• Rafael Holdings reported a net loss attributable to the company of $4.8 million, or $0.19 per share, for the third fiscal quarter ended April 30, 2025, a significant decrease from a net loss of $32.4 million, or $1.36 per share, in the prior year period.
• For the first nine months of fiscal year 2025, the net loss attributable to Rafael Holdings was $18.4 million, or $0.73 per share, down from $29.9 million, or $1.26 per share, in the year-ago period.
• The decrease in net loss is primarily attributed to non-cash items, specifically the absence of an $89.9 million in-process R&D expense related to the Cornerstone acquisition and a $31.3 million recovery of receivables from Cornerstone that impacted the prior year's results, along with lower unrealized losses on Cyclo equity in the current quarter.
• The company completed its merger with Cyclo Therapeutics on March 25, 2025.
• The Phase 3 TransportNPC clinical trial for Trappsol Cyclo, targeting Niemann-Pick Disease Type C1, is fully enrolled, with 48-week interim analysis results anticipated later in June 2025.
• Rafael Holdings closed a $25 million rights offering on June 4, 2025, generating net proceeds of $24.9 million, which included a backstop commitment from the Jonas family.
• Cash and cash equivalents stood at $37.9 million as of April 30, 2025.
• Research and development expenses increased to $3.0 million for the quarter and $5.3 million for the nine months, primarily due to the inclusion of Cyclo Therapeutics and the consolidation of Cornerstone and Day Three.
• General and administrative expenses also increased to $3.2 million for the quarter and $8.3 million for the nine months due to the same consolidations.

Sentiment

Score: 7

Explanation: The sentiment is positive due to a significant reduction in net loss, successful completion of a strategic merger, a substantial capital raise, and the full enrollment of a pivotal Phase 3 clinical trial with results expected soon. While expenses increased due to consolidation, the overall financial position and clinical progress indicate a favorable outlook, contingent on the upcoming trial results.

Positives

• Significant reduction in net loss for both the third quarter (to $4.8 million from $32.4 million) and the first nine months (to $18.4 million from $29.9 million) of fiscal year 2025.
• Successful completion of the merger with Cyclo Therapeutics on March 25, 2025, integrating a key clinical-stage asset.
• Full enrollment of the pivotal Phase 3 TransportNPC clinical trial for Trappsol Cyclo, indicating progress towards potential market approval.
• Anticipated release of 48-week interim analysis results for the Phase 3 TransportNPC study later in June 2025, which could be a significant catalyst.
• Successful closing of a $25 million rights offering on June 4, 2025, enhancing the company's financial position with $24.9 million in net proceeds.
• Increased cash and cash equivalents to $37.9 million as of April 30, 2025, prior to the rights offering proceeds.

Negatives

• Increased research and development expenses to $3.0 million for the quarter and $5.3 million for the nine months, reflecting higher operational costs post-merger and consolidations.
• Increased general and administrative expenses to $3.2 million for the quarter and $8.3 million for the nine months, also due to expanded operations.
• The reduction in net loss is largely attributable to non-cash items and the absence of large one-time expenses from the prior year, rather than a fundamental improvement in core operating profitability.

Risks

• Forward-looking statements are subject to known and unknown risks, uncertainties, and other important factors that may cause actual results to differ materially from expectations.
• Reliance on the potential, safety, efficacy, and regulatory and clinical progress of product candidates, which are inherently uncertain.
• Risks associated with the further evaluation of clinical data and the potential of the company's pipeline, including internal cancer metabolism research programs.
• Specific risks disclosed under the caption 'Risk Factors' in the company's Annual Report on Form 10-K for the year ended July 31, 2024, and other SEC filings.

Future Outlook

Rafael Holdings anticipates reporting topline data from the 48-week interim analysis of the pivotal Phase 3 TransportNPC study for Trappsol Cyclo, targeting Niemann-Pick Disease Type C1, later in June 2025. The company's enhanced financial position from the recent rights offering is expected to support the advancement of this potential new treatment option.

Management Comments

• "We are pleased to have completed our merger with Cyclo Therapeutics and look forward to reporting the topline data from the 48-week interim analysis of the pivotal Phase 3 TransportNPC study evaluating Trappsol Cyclo for the treatment of Niemann-Pick Disease Type C1 anticipated later this month." Howard Jonas, Chief Executive Officer, Executive Chairman and Chairman of the Board of Rafael Holdings.
• "We have enhanced our financial position with the closing of a $25 million rights offering earlier this month which will support advancing this potential new treatment option for patients suffering from this rare genetic disease." Howard Jonas, Chief Executive Officer, Executive Chairman and Chairman of the Board of Rafael Holdings.

Industry Context

Rafael Holdings operates within the highly specialized and capital-intensive biotechnology and pharmaceutical sectors, with a focus on rare genetic diseases like Niemann-Pick Disease Type C1, as well as cancer metabolism and medical devices. The completion of the Cyclo Therapeutics merger aligns with a broader industry trend of consolidation and strategic acquisitions to bolster pipelines and leverage synergies, particularly in the rare disease space where high unmet medical needs can command premium valuations upon successful drug development. The ongoing Phase 3 trial for Trappsol Cyclo positions the company at a critical juncture, as positive results could significantly de-risk the asset and attract further investment, reflecting the industry's reliance on clinical milestones for value creation. The capital raise through a rights offering is a common mechanism for biotech companies to fund expensive late-stage clinical trials and general operations.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess against global industry benchmarks. Therefore, a direct comparison to industry standards based solely on the provided text is not feasible.

Related Party Transactions

• The Jonas family funded the backstop commitment for the $25 million rights offering.

Stakeholder Impact

• Shareholders: The significant reduction in net loss and successful capital raise could be viewed positively, potentially stabilizing or increasing share value. The upcoming Phase 3 trial results represent a major catalyst for future share price movement.
• Patients (Niemann-Pick Disease Type C1): The advancement of Trappsol Cyclo through a fully enrolled Phase 3 trial offers hope for a new treatment option for a rare and fatal genetic disease.
• Employees: The merger and consolidation activities suggest an expanded operational scope, potentially impacting employment and organizational structure.
• Creditors: The enhanced cash position from the rights offering could improve the company's ability to meet its financial obligations.

Next Steps

• Reporting topline data from the 48-week interim analysis of the pivotal Phase 3 TransportNPC study for Trappsol Cyclo later in June 2025.
• Advancing Trappsol Cyclo as a potential new treatment option for Niemann-Pick Disease Type C1.
• Continued operations and development of other portfolio companies including LipoMedix Pharmaceuticals, Cornerstone Pharmaceuticals, Rafael Medical Devices, and Day Three Labs.

Key Dates

Recommendation

Keywords

Rafael Holdings, RFL, Cyclo Therapeutics, Trappsol Cyclo, Niemann-Pick Disease Type C1, NPC1, Phase 3 clinical trial, TransportNPC, biotechnology, pharmaceuticals, rare disease, earnings report, financial results, rights offering, capital raise, SEC filing, 8-K, clinical stage, cancer metabolism, medical devices, cannabis industry